NLS

On November 13, the day before the company's Extraordinary General Meeting, it was announced that Mikael Dolsten will not seek election to the Board of Directors as otherwise announced in the notice convening the meeting.

Lytix Biopharma has announced promising interim results from an ongoing investigator-initiated Phase 2 NeoLIPA study evaluating ruxotemitide (formerly LTX-315) in combination with pembrolizumab as neoadjuvant therapy in resectable melanoma.

Authera has received funding from the Research Council of Norway through the Innovation Project for the Industrial Sector.

Anders Tuv’s varied background as an investor, founder, and company builder has taken him to the very center of the multidisciplinary nature of creating a life science company. As Managing Director at Radforsk Invest he truly enjoys shaping strategies and helping startups implement and realize innovations.

The company has initiated a Phase IIa clinical trial to evaluate the safety and biomarker-based efficacy of AT-001 in individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD).

Donna Haire will join FluoGuide full time as Chief Operating Officer to lead development, including regulatory strategy and the US clinical program toward the first approval of FG001 in high-grade glioma.